Recruitment

Recruitment Status
Active, not recruiting
Estimated Enrollment
1500

Summary

Conditions
Pulmonary Arterial Hypertension
Type
Observational
Design
Observational Model: CohortTime Perspective: Prospective

Participation Requirements

Age
Between 18 years and 100 years
Gender
Both males and females

Description

The protocol is designed to lead to new understanding of patients with pulmonary hypertension and right heart dysfunction, based on molecular, clinical, hemodynamic and radiographic characteristics. New classifications will be a product of association of these in depth phenotypic descriptions with s...

The protocol is designed to lead to new understanding of patients with pulmonary hypertension and right heart dysfunction, based on molecular, clinical, hemodynamic and radiographic characteristics. New classifications will be a product of association of these in depth phenotypic descriptions with specific molecular mechanisms of pathogenesis. The protocol will be implemented to lead to identification of both sub-phenotypes of lung vascular disease and to biomarkers of disease that may be useful for early diagnosis or for assessment of interventions to prevent or treat this condition. A longitudinal study in a subset of the participants enrolled in the parent cross-sectional study will: Retest participants at a minimum 6 month interval from initial evaluation to collect a core set of clinical and OMICS features. This will include survival, clinical staging, clinical group assignment, 6-minute walk, echocardiography, and blood for a broad collection of selected OMICS tests, to include proteomics and other variables found to be informative in the initial set. Associate and compare OMICS data with clinical sets and OMICS clusters between baseline and follow-up interval, with attention to reproducibility, predictive capacity as biomarkers for diagnosis, disease progression, phenotypic changes, functional capacity, therapeutic response and survival.

Tracking Information

NCT #
NCT02980887
Collaborators
  • Brigham and Women's Hospital
  • Columbia University
  • Weill Medical College of Cornell University
  • Johns Hopkins University
  • Mayo Clinic
  • University of Arizona
  • Vanderbilt University
Investigators
Study Chair: Nicholas S Hill, MD Tufts University Medical Center Study Director: Lei Xiao, MD National Heart, Lung, and Blood Institute (NHLBI)